It is not clear how treatment with VPA/hydralazine reversed the downregulation of Cdkn2a. No significant differences in DNA methylation in the promoter region, 5′-UTR or the 1st exon of Cdkn2a were seen in the mammary tumors between the control and HF offspring. This evidence concerns the gene CDKN2A and breast cancer.